Immucell (ICCC) Cash from Operations (2010 - 2025)
Immucell's (ICCC) quarterly Cash from Operations came in at 482541.0 in Q4 2025, up 15915.83% YoY from N/an in Q4 2024, and up 140.8% on a QoQ basis from 1182583.0 in Q3 2025.
Immucell (ICCC) Cash from Operations (2010 - 2025) Analysis & Trends
Immucell (ICCC) has 16 years of Cash from Operations data on file, last reported at 482541.0 in Q4 2025.
- Quarterly Cash from Operations rose 15915.83% year-over-year to 482541.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 2475292.0 (up 591.61% YoY) and the FY2025 annual result came in at 2475292.0, up 591.61% from the prior year.
- Cash from Operations climbed to 482541.0 in Q4 2025, from 1182583.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 1601498.0 in Q2 2025 to a low of 2761985.0 in Q1 2023.
- A 5-year average of 121537.1 and a median of 127970.0 in 2021 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations sank 585.75% — and 2025, when it soared 15915.83%.
- Tracing ICCC's Cash from Operations over 5 years: stood at 587893.0 in 2021, then sank by 320.76% to 1297822.0 in 2022, then jumped by 44.29% to 723071.0 in 2023, then soared by 99.58% to 3051.0 in 2024, then soared by 15915.83% to 482541.0 in 2025.
- The last three Cash from Operations figures came in at 482541.0 (Q4 2025), 1182583.0 (Q3 2025), and 1601498.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 326.72 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -88.83 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 728.46 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.27 Mn |
| 10 | Immucell | 92.01 Mn | 83.15 Mn | 2.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 482,541.00 |
| Dec 31, 2025 | 482,541.00 |
| Sep 30, 2025 | -1.18 Mn |
| Sep 30, 2025 | -1.18 Mn |
| Jun 30, 2025 | 1.60 Mn |
| Jun 30, 2025 | 1.60 Mn |
| Mar 31, 2025 | 1.57 Mn |
| Mar 31, 2025 | 1.57 Mn |
| Dec 31, 2024 | -3,051.00 |
| Dec 31, 2024 | -3,051.00 |
| Sep 30, 2024 | -639,331.00 |
| Sep 30, 2024 | -639,331.00 |
| Jun 30, 2024 | 581,780.00 |
| Jun 30, 2024 | 581,780.00 |
| Mar 31, 2024 | 418,505.00 |
| Mar 31, 2024 | 418,505.00 |
| Dec 31, 2023 | -723,071.00 |
| Dec 31, 2023 | -723,071.00 |
| Sep 30, 2023 | -507,754.00 |
| Sep 30, 2023 | -507,754.00 |